Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 13/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | MMP13 | P45452 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6669425 | 0.88 | MAPK1 (0.45) | EGLN1MAPK1GAAALDH1A1KMT2A | |
| SCHEMBL6670932 | 0.85 | MAPK1 (0.41) | EGLN1MAPK1GAAALDH1A1KMT2A | |
| SCHEMBL7841422 | 0.84 | MAPK1 (0.45) | EGLN1MAPK1RXFP1 | |
| SCHEMBL6713757 | 0.83 | EGLN1 (0.51) | EGLN1ALDH1A1 | |
| SCHEMBL6713689 | 0.80 | GAA (0.46) | EGLN1GAAALDH1A1KMT2AMAOB | |
| SCHEMBL6283724 | 0.79 | RXFP1 (0.43) | MAPK1ALDH1A1KMT2ARXFP1 | |
| SCHEMBL6284294 | 0.76 | RXFP1 (0.46) | MAPK1KMT2ARXFP1 | |
| SCHEMBL6766761 | 0.76 | MAPK1 (0.45) | EGLN1MAPK1RXFP1 | |
| SCHEMBL6283195 | 0.76 | RXFP1 (0.44) | MAPK1KMT2ARXFP1 | |
| SCHEMBL6280215 | 0.76 | MAPK1 (0.40) | MAPK1GAAALDH1A1KMT2ARXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040180910-A1 | Heterocycle carboxamides as antiviral agents | SCHNUTE MARK E (US) | 2004-09-16 | — | — | US | claimed |
| US-20040176366-A1 | Method of preventing or treating atherosclerosis or restenosis | WATHEN MICHAEL W | 2004-09-09 | — | — | US | claimed |
| EP-1363907-A2 | HETEROCYCLE CARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2003-11-26 | — | — | EP | claimed |
| US-20020019397-A1 | Heterocycle carboxamides as antiviral agents | PHARMACIA & UPJOHN COMPANY | 2002-02-14 | — | — | US | claimed |
| WO-2002004443-A2 | HETEROCYCLE CARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2002-01-17 | — | — | WO | claimed |
| US-20040180910-A1 | Heterocycle carboxamides as antiviral agents | SCHNUTE MARK E (US) | 2004-09-16 | — | — | US | disclosed |
| US-20040176366-A1 | Method of preventing or treating atherosclerosis or restenosis | WATHEN MICHAEL W | 2004-09-09 | — | — | US | disclosed |
| US-6730682-B2 | HERPES VIRUS | PHARMACIA & UPJOHN COMPANY | 2004-05-04 | — | — | US | disclosed |
| EP-1363907-A2 | HETEROCYCLE CARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2003-11-26 | — | — | EP | disclosed |
| US-20020019397-A1 | Heterocycle carboxamides as antiviral agents | PHARMACIA & UPJOHN COMPANY | 2002-02-14 | — | — | US | disclosed |
| WO-2002004443-A2 | HETEROCYCLE CARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2002-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176366-A1 | Method of preventing or treating atherosclerosis or restenosis | LDLR, NR1H3, NR1H2 | EGLN1 1486/4885MAPK1 904/4885GAA 1869/4885 |
| US-20040180910-A1 | Heterocycle carboxamides as antiviral agents | ZC3HAV1, ZC3HAV1L, HDAC1 | EGLN1 134/4885MAPK1 1827/4885GAA 1182/4885 |
| US-20020019397-A1 | Heterocycle carboxamides as antiviral agents | ZC3HAV1, ZC3HAV1L, HDAC1 | EGLN1 134/4885MAPK1 1827/4885GAA 1182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.